Traditional Chinese drugmakers prep to invade the West

The makers of traditional Chinese medicines are preparing for the world stage. The 7th World Congress of Chinese Medicine in Xinhua last week carried an unlikely theme that included such phrases as "clinical practice" and "scientific research."

Presentation titles did little to mask the ambitions of medicine makers. "Technical requirements for registration of Chinese medicine in the EU" and "Quality control of Chinese medicine" were among them.

And their efforts are hardly restricted to manufacturing topics: they are intent on proving the benefit of their treatments. Efforts are under way to create clinical trial protocols for traditional medicines that acknowledge their custom nature while meeting the proof standards of Western drug regulators.

- here's the article

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.